Neos Therapeutics Inc. (NEOS) Given Average Recommendation of “Buy” by Analysts
Neos Therapeutics Inc. (NASDAQ:NEOS) has been given an average rating of “Buy” by the five brokerages that are currently covering the company. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $30.50.
NEOS has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Neos Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 price objective for the company in a report on Thursday, October 13th. BMO Capital Markets restated a “buy” rating on shares of Neos Therapeutics in a report on Friday, November 11th.
Hedge funds have recently made changes to their positions in the company. Perceptive Advisors LLC boosted its stake in shares of Neos Therapeutics by 526.9% in the second quarter. Perceptive Advisors LLC now owns 626,876 shares of the company’s stock worth $4,611,000 after buying an additional 526,876 shares during the period. BlackRock Fund Advisors boosted its stake in shares of Neos Therapeutics by 58.5% in the second quarter. BlackRock Fund Advisors now owns 566,112 shares of the company’s stock worth $5,254,000 after buying an additional 209,054 shares during the period. Vanguard Group Inc. boosted its stake in shares of Neos Therapeutics by 12.3% in the second quarter. Vanguard Group Inc. now owns 293,989 shares of the company’s stock worth $2,729,000 after buying an additional 32,266 shares during the period. BlackRock Institutional Trust Company N.A. boosted its stake in shares of Neos Therapeutics by 52.7% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 172,536 shares of the company’s stock worth $1,601,000 after buying an additional 59,533 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of Neos Therapeutics by 3.5% in the third quarter. Northern Trust Corp now owns 140,498 shares of the company’s stock worth $924,000 after buying an additional 4,687 shares during the period. 34.32% of the stock is owned by hedge funds and other institutional investors.
Neos Therapeutics (NASDAQ:NEOS) traded down 3.571% during mid-day trading on Monday, reaching $7.425. The company’s stock had a trading volume of 36,107 shares. Neos Therapeutics has a 1-year low of $5.30 and a 1-year high of $16.41. The stock’s market capitalization is $119.25 million. The stock’s 50 day moving average price is $6.81 and its 200 day moving average price is $7.99.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Stock Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related stocks with our FREE daily email newsletter.